Last updated: June 24, 2026
Pfizer v. Ranbaxy (1:07-cv-00138) Litigation Summary and Patent/Exclusivity Impact
Pfizer Inc. v. Ranbaxy Laboratories Limited, docket 1:07-cv-00138 (filed 2007) is a federal patent infringement case tied to Pfizer’s branded product IP and Ranbaxy’s generic entry plans. The case’s business impact is best assessed through three lenses: (1) which asserted patents covered the branded formulation, manufacturing process, and/or method-of-use; (2) whether the case resolved via settlement with a stated launch/“carve-out” date; and (3) what effect any final judgments and claim constructions had on subsequent Paragraph IV filings and other generic workstreams.
Result: No complete, verifiable litigation record (complaint claims/patents asserted, court rulings, settlement terms, final judgment date, and appellate posture) is available in the prompt. Under the operating constraints, a complete and accurate litigation summary cannot be produced.
What patents were asserted in Pfizer Inc. v. Ranbaxy Laboratories Limited 1:07-cv-00138?
Answer: Not stated in the provided information.
Which Pfizer product and Orange Book patents were in-suit?
Answer: Not stated in the provided information.
Were formulation, process, and/or method-of-use claims asserted?
Answer: Not stated in the provided information.
What was the procedural timeline for 1:07-cv-00138 (complaint, claim construction, summary judgment, trial)?
Answer: Not stated in the provided information.
Key dates and milestones
Answer: Not stated in the provided information (no docket events, hearing dates, or orders supplied).
How did the court rule on infringement, validity, and noninfringement defenses?
Answer: Not stated in the provided information.
Was there a finding on patent invalidity (35 USC § 102/103/112) or unenforceability?
Answer: Not stated in the provided information.
Did the case settle, and what launch dates or injunction terms were agreed with Ranbaxy?
Answer: Not stated in the provided information.
Settlement terms that affect generic entry risk
Answer: Not stated in the provided information (no settlement agreement text or reported terms supplied).
What Paragraph IV or FDA exclusivity exposure did this litigation target?
Answer: Not stated in the provided information.
What FDA pathway and ANDA status were at issue?
Answer: Not stated in the provided information.
Which other generic companies and parallel cases were affected by the outcome?
Answer: Not stated in the provided information.
Downstream impact on subsequent filings and approvals
Answer: Not stated in the provided information.
Key Takeaways
- A litigation-summary and analysis requires at minimum: asserted patent numbers, product/Orange Book listing, docket rulings or settlement terms, and final disposition.
- The provided prompt includes only the case caption and docket identifier, which is insufficient for an accurate litigation analysis under the required standard.
FAQs
-
What is the case outcome for Pfizer v. Ranbaxy (1:07-cv-00138)?
Not stated in the provided information.
-
Which specific patents did Pfizer assert in 1:07-cv-00138?
Not stated in the provided information.
-
Did Ranbaxy receive an injunction or permission to market based on the court’s decisions?
Not stated in the provided information.
-
Was the dispute resolved via settlement, consent judgment, or trial judgment?
Not stated in the provided information.
-
How did the case influence FDA approval timelines for competing generic applicants?
Not stated in the provided information.
References
- Pfizer Inc. v. Ranbaxy Laboratories Limited, 1:07-cv-00138 (U.S. District Court docket).
